DUBLIN--(BUSINESS WIRE)--The "Transdermal Drug Delivery System Market by Type (Patches and Semisolid formulations), Applications (Pain Management, Central Nervous System Disorders, Hormonal Applications, Cardiovascular Diseases), End User, and Region - Global Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.
The transdermal drug delivery systems market is projected to reach USD 7,068.8 million by 2023 from an estimated USD 5,677.3 million in 2018, at a CAGR of 4.5%.
Market growth is largely driven by the global increase in the prevalence of chronic diseases. In addition, technological advancements in transdermal drug delivery systems are expected to support market growth in the coming years. However, drug failures and recalls of transdermal drug delivery systems are expected to restrain market growth to a certain extent.
Transdermal drug delivery systems are a category of controlled drug delivery systems, which deliver drugs through the skin in a predetermined and controlled rate. Transdermal drug delivery systems, such as transdermal patches, are mainly used by patients suffering from chronic diseases/disorders such as chronic pain, central nervous system disorders (such as Parkinson's disease), hormonal disorders, and cardiovascular diseases.
In this report, the market is further segmented based on type, applications, end users, and regions. The transdermal drug delivery systems market is dominated by Hisamisu Pharmaceutical (Japan), Mylan (US), UCB SA (Belgium), Luye Pharma (China), and GlaxoSmithKline (UK). These players accounted for ~70% to 75% of the market in 2017.
These players adopted major growth strategies such as product launches & approvals, collaborations, and expansions.
Key Topics Covered:
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Transdermal Drug Delivery Systems Market, By Type
7 Transdermal Drug Delivery Systems Market, By Application
8 Transdermal Drug Delivery Systems Market, By End User
9 Transdermal Drug Delivery Systems Market, By Region
10 Competitive Landscape
11 Company Profiles
- Boehringer Ingelheim International GmbH
- Endo International, Inc.
- Glaxosmithkline PLC
- Hisamitsu Pharmaceutical Co., Inc.
- Johnson & Johnson (J&J)
- Lavipharm
- Lead Chemicals Co., Inc.
- Luye Pharma Group
- Mylan N.V.
- Novartis AG
- Purdue Pharma L.P.
- UCB S.A.
For more information about this report visit https://www.researchandmarkets.com/research/n2bp3g/transdermal_drug?w=4
